PBMs could soon feel the regulatory sting

From Congress to the FTC to state legislatures, regulators are cracking the whip against PBMs.

By Karissa Waddick • Aug. 4, 2023

Is the COVID-19 market crashing?

Pfizer’s recent earnings report could foretell major trouble in the market for pandemic products.

By Meagan Parrish • Aug. 3, 2023

Explore the Trendline➔

Clinical trial diversity

As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.

By PharmaVoice staff

Putting purpose over profits, this pharma takes on the important issues

Afaxys is a self-described "socially conscious" contraceptive healthcare company serving an unusual demographic for pharma: the public health sector.

By Alexandra Pecci • Aug. 1, 2023

A pharma banking on the success of past blockbusters

180 Life Sciences is on a mission to see if the anti-TNF technology that produced a blockbuster could work for a range of other conditions.

By Kelly Bilodeau • July 31, 2023

Big Pharma CEOs get candid about pricing and M&A

Head honchos at the biggest pharma companies reporting second-quarter earnings dig into the topics du jour.

By Michael Gibney • July 28, 2023

Biogen’s layoffs are the latest in an industrywide slip

Over 100 biotech companies so far this year have cut staff due to persistent funding challenges.

By Karissa Waddick • July 26, 2023

With OTC birth control approved, access battles have just begun

Perrigo received the first FDA approval for an OTC birth control pill. Now, its global VP of women’s health says the company is working on the next challenge — affordability.  

By Karissa Waddick • July 26, 2023

For Merck, understanding maternal mortality is the first step toward equity

Merck has invested for more than a decade in reducing maternal death rates in the U.S. and globally. Now for the next chapter.

By Michael Gibney • July 25, 2023

Responding to declining pharmacy reimbursement with an alternative channel strategy

Commercial teams need to accept the reality of declining pharmacy reimbursement as an important variable in their go-to-market equation.

By Daniel Johnson, Sr. Director of Product Marketing at Phil Inc. • July 24, 2023

A leading CRO’s chief exec on why a ‘brave new world’ of clinical research is here

Peter Benton, co-CEO of Worldwide Clinical Trials, explains how the rise of the mid-sized pharma company has changed drug R&D.  

By Taren Grom and Meagan Parrish • July 20, 2023

4 controversial measures in Congress’ pandemic preparedness bill

Efforts to tackle drug pricing, shortages, the speed of FDA approvals and more have been mixed into Congress’ efforts to reauthorize the Pandemic and All Hazards Preparedness Act.

By Karissa Waddick • July 20, 2023

As biologics boom, here’s how manufacturers are keeping up

Stevanato’s focus on biologic-related vials and delivery devices has put it in a unique position amid a quickly growing market.

By Michael Gibney • July 19, 2023

AI’s great expectations

With AI expectations riding high, here’s a look at some areas where the technology could be most useful in drug development. 

By Karissa Waddick • July 19, 2023

Threads joins the social media fray. Here’s what it means for pharma marketers.

Meta’s new platform is drawing Twitter comparisons and could hold potential for pharma marketers in patient and HCP communication.

By Karissa Waddick • July 18, 2023

DCTs create fresh privacy challenges for review boards. Now there are guidelines.

A new toolkit developed by industry stakeholders paves the way for faster reviews.

By Kelly Bilodeau • July 17, 2023

Flagship, PhRMA prioritize experience in hot summer exec changes

With major projects brewing at both organizations, these new leaders will hit the ground running. 

By Karissa Waddick • July 14, 2023

Novo’s workhorse Ozempic could shine in new areas

Besides its popularity as a weight loss drug, Ozempic and treatments like it are being investigated for Alzheimer’s, liver disease and other surprising indications.

By Michael Gibney • July 13, 2023

FDA’s upcoming psychedelic review looms large for a budding industry

A new psychedelic guidance from the agency gives a clue into how it could analyze drugs in the space, but industry leaders are eager for more.

By Karissa Waddick • July 12, 2023

Merck’s New Jersey campus is getting a biotech makeover

With a purchase of the pharma giant’s Kenilworth campus, Onyx Equities is looking to make the spot a go-to biotech hub.

By Michael Gibney • July 11, 2023

Cancer R&D is shifting — here’s what’s changing most

A report from IQVIA shows China gaining ground in cancer drug R&D, and a growing industry focus on new drug targets.

By Kelly Bilodeau • July 10, 2023

Following FDA’s full approval of Leqembi, here’s what else is in the Alzheimer’s pipeline

Leqembi’s U.S. approval is a milestone in Alzheimer’s research and medicine — and there are a few other late-stage biologic drugs that could follow.

By Michael Gibney • July 7, 2023

Pharma’s strike-from-all-sides attack on the IRA could be decided by the Supreme Court

New lawsuits challenging the Inflation Reduction Act’s price negotiation program hit the government with multiple Constitution-based challenges.

By Alexandra Pecci • July 6, 2023

A BMS exec’s journey around the world in 90 days

As BMS grapples with upcoming patent cliffs, Emma Charles, the new SVP of intercontinental markets, is focused on expanding its footprint.

By Karissa Waddick • July 5, 2023

Women’s healthcare investments are hot. So where are the new menopause drugs?

NK3 receptor antagonists offer a new option, but experts say more are needed.

By Kelly Bilodeau • July 5, 2023

The stories you’ve read the most in 2023 (so far)

From staff shortages to presidential candidates and the M&A outlook, here are our most-read stories from the first half of the year.

By PharmaVoice Staff • July 3, 2023